Cargando…
Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson’s disease. We employed a novel, parallel, compound-centric approach to identify a potent and selective LRRK2 inhibitor LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces...
Autores principales: | Deng, Xianming, Dzamko, Nicolas, Prescott, Alan, Davies, Paul, Liu, Qingsong, Yang, Qingkai, Lee, Jiing-Dwan, Patricelli, Matthew P., Nomanbhoy, Tyzoon K., Alessi, Dario R., Gray, Nathanael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287420/ https://www.ncbi.nlm.nih.gov/pubmed/21378983 http://dx.doi.org/10.1038/nchembio.538 |
Ejemplares similares
-
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones
por: Deng, Xianming, et al.
Publicado: (2013) -
The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling
por: Dzamko, Nicolas, et al.
Publicado: (2012) -
Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
por: Deng, Xianming, et al.
Publicado: (2011) -
Inhibition of LRRK2 kinase activity leads to dephosphorylation of
Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic
localization
por: Dzamko, Nicolas, et al.
Publicado: (2010) -
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)